A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Prog

Learn how it’s Safe@Inova

Get the facts on how we’re ensuring safety at our locations, our PPE safety requirements, and more, so you know it’s safe to receive the care you need—as well as safe for us to continue delivering your care. Whether your visit is for routine care, emergency care, or COVID-19 care, you have a nationally recognized leader in safety, ready for you. See temporary restricted visitation policy.

General Information

Age Group

Adults

Status

Recruiting

Protocol Number

NCT03834506

Background Information

The purpose of this study is to test the safety of the study drug, pembrolizumab, in combination with a chemotherapy plus a steroid on participants with mCRPC with disease progression after being treated with a NHA. The study will determine the safety and efficacy of pembrolizumab compared to placebo (a look-alike with no active ingredients) in combination with a chemotherapy and a steroid. Pembrolizumab (MK-3475), also known as KEYTRUDA®.

For more information go to https://clinicaltrials.gov/ct2/show/NCT03834506

Offered At

Inova Schar Cancer Institute
A department of Inova Fairfax Hospital
8081 Innovation Park Blvd.
Fairfax, VA 22031

Eligibility Information

Male participants with mCRPC in the pre-chemotherapy stage of treatment
Current evidence of metastatic disease
Additional eligibility in protocol

Ineligibility Information

Active autoimmune disease
Gastrointestinal disorders affecting absorption
Active central nervous system metastases
Additional ineligibility in protocol